Furthermore, NHWD870 treatment restored osimertinib sensitivity by disrupting APT1-mediated depalmitoylation of MST1, indicating that targeting BRD4 may contribute to treating osimertinib-resistant NSCLC. This evidence concerns the gene BRD4 and non-small cell lung carcinoma.